NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension

@article{Keck2019NI956QGC006AP,
  title={NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension},
  author={Mathilde Keck and Hugo de Almeida and Delphine Comp{\`e}re and Nicolas Inguimbert and Adrien Flahault and Fabrice Balavoine and B. Roques and Catherine Llorens-Cortes},
  journal={Hypertension},
  year={2019},
  volume={73},
  pages={1300–1307}
}
Brain renin-angiotensin system hyperactivity has been implicated in the development and maintenance of hypertension. [...] Key Result NI929 is 10× more efficient than EC33 at inhibiting recombinant mouse aminopeptidase A activity in vitro.Expand
11 Citations
Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions
TLDR
Orally active APA inhibitor prodrugs, by blocking brain RAS activity, represent promising novel strategy for treating hypertension.
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials
TLDR
A narratively review the published phase I–II literature on the safety and efficacy of APA inhibitors in the management of patients with hypertension and a summary of ongoing clinical trials and future perspectives are presented.
Evolution of a New Class of Antihypertensive Drugs: Targeting the Brain Renin-Angiotensin System.
TLDR
Firibastat could represent the first drug of a novel class of antihypertensive drugs targeting the brain renin-angiotensin system in hypertensive patients, according to World Health Organization.
Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies
TLDR
Novel therapeutic agents being developed as RAAS inhibitors that show prominent effects in both preclinical and clinical studies are discussed, highlighting the need for improvement in the efficacy of existing drugs in the absence of new prominent antihypertensive drugs.
The Renin-Angiotensin System in the Central Nervous System and Its Role in Blood Pressure Regulation
TLDR
How the development of state-of-the-art technology has made it possible to address fundamental questions related to how the renin-angiotensin system (RAS) operates within the brain from the neurophysiological and molecular perspective is discussed.
Brain Renin–Angiotensin System as Novel and Potential Therapeutic Target for Alzheimer’s Disease
TLDR
The evidence for the function of the brain RAS in cognition and AD pathogenesis is revised and the evidence that links it to hypercholesterolemia and other risk factors is summarized.
LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism
TLDR
The effects of LIT01-196 following systemic administrations on arterial blood pressure, heart rate, fluid balance and electrolytes in conscious normotensive and hypertensive deoxycorticosterone acetate-salt rats are investigated to constitute a novel approach for the treatment of hypertension.
IRAP Inhibitors: M1-Aminopeptidase Family Inspiration
The insulin regulated aminopeptidase (IRAP) has been proposed as an important therapeutic target for indications including Alzheimer’s disease and immune disorders. To date, a number of IRAP
Angiotensin II, dopamine and nitric oxide. An asymmetrical neurovisceral interaction between brain and plasma to regulate blood pressure
TLDR
It is suggested that the neuronal activity related to the production of nitric oxide in plasma is also lateralized and, consequently, changes in plasma nitrics influence neuronal function and provides a new aspect revealing the complexity of the blood pressure regulation.
New and emerging cardiovascular and antihypertensive drugs
TLDR
This review focuses on newly released and emerging new cardiovascular drugs that in preliminary studies have been successful in the treatment of hypertension, CVD, heart failure, stroke, and type 2 diabetes mellitus.
...
1
2
...

References

SHOWING 1-10 OF 46 REFERENCES
Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure: A New Strategy for Treating Hypertension
TLDR
RB150, a dimer of the selective aminopeptidase A inhibitor, EC33, generated by creating a disulfide bond, may be the prototype of a new class of centrally active antihypertensive agents.
Central Antihypertensive Effects of Orally Active Aminopeptidase A Inhibitors in Spontaneously Hypertensive Rats
TLDR
RB150 may be the prototype of a new class of centrally active antihypertensive agents that might be used in combination with classic systemic renin-angiotensin system blockers to improve blood pressure control.
Aminopeptidase A inhibitors as potential central antihypertensive agents.
TLDR
In rats, ICV injection of the selective APA inhibitor EC33 blocked the pressor response of exogenous AngII, suggesting that the conversion of AngII to Ang III is required to increase blood pressure (BP), and demonstrates that AngIII is a major effector peptide of the brain RAS, exerting tonic stimulatory control over BP.
Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats
TLDR
The results strengthen the interest of developing RB150 as a novel central-acting antihypertensive agent and evaluating its efficacy in salt-sensitive hypertension.
Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension.
TLDR
It is reported that brain AngIII exerts a tonic stimulatory effect on blood pressure in a model of salt-dependent hypertension, the DOCA-salt rat, characterized by a depressed systemic but a hyperactive brain RAS, and suggested that RB150, a potent systemically active APA inhibitor, could be the prototype of a new class of antihypertensive agents for the treatment of certain forms of hypertension.
PC18, a Specific Aminopeptidase N Inhibitor, Induces Vasopressin Release by Increasing the Half-Life of Brain Angiotensin III
TLDR
Results indicate that in vivo, in the mouse brain, APN inhibition by PC18 increases the half-life of endogenous AngIII, resulting in an enhanced vasopressin release.
Synthesis and in vitro activities of new non-peptidic APA inhibitors.
  • N. Inguimbert, P. Coric, +5 authors B. Roques
  • Chemistry, Medicine
    The journal of peptide research : official journal of the American Peptide Society
  • 2005
TLDR
New non-peptidic inhibitors able to interact with the S1 and S'1 subsites of the targeted enzyme are synthesized to enhance the bioavailability and potency of EC 33, the APA inhibitor.
Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.
TLDR
Ang III behaves as one of the main effector peptides of the brain renin-angiotensin system in the control of vasopressin release, demonstrating for the first time that APA and APN are involved in vivo in the metabolism of brain Ang II and Ang III.
"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes.
TLDR
The analgesic potencies of the "mixed inhibitor-prodrug" RB 101 were three times greater than those of a similar combined dose of its two constitutive moieties, and the separation of the two diastereoisomers constituting RB 101 showed that the analgesia has a stereochemical dependence.
Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats
TLDR
The close correspondence between the distribution of aminopeptidase A activity and angiotensin receptors and nerve terminals in the brain associated with the observation that aminOPEptid enzyme A activity was overactivated in the spontaneously hypertensive rats suggest that this enzyme may contribute, at least in part, to the regulation of cardiovascular functions by its ability to convert ang Elliotensin II to angiotENSin III.
...
1
2
3
4
5
...